Astria Therapeutics (ATXS) The Citizens JMP Life Sciences Conference 2025 summary

Strategic focus and pipeline overview

• Focused on developing first-choice therapies for allergic and immunologic diseases, prioritizing efficacy, safety, and low treatment burden.

• Lead program Navenibart targets hereditary angioedema (HAE) with a monoclonal antibody inhibiting plasma kallikrein, showing >90% attack rate reduction in phase 1b/2 trials.

• STAR-0310, a monoclonal antibody antagonist of OX40, is in phase 1a trials for T cell-mediated diseases, with initial results expected in Q3.

Market landscape and competitive positioning

• HAE market projected to reach $5.4 billion by 2030, driven by earlier diagnosis, increased use of preventative therapies, and geographic expansion.

• Navenibart aims to become a market leader by offering infrequent dosing (every 3 or 6 months) and a strong efficacy profile.

• Market research indicates significant patient willingness to switch to therapies with better efficacy, safety, and convenience.

Clinical data and trial design

• Phase 1b/2 data for Navenibart showed >90% reduction in attack rate, moderate to severe attacks, and rescue medication use, with favorable safety.

• Navenibart is engineered for extended half-life, enabling infrequent dosing; phase 3 trial tests both 3- and 6-month regimens globally.

• Long-term extension (AlphaSolar) will provide additional safety and durability data mid-year, with all original patients enrolling.

• Phase 3 primary endpoint is percent reduction in attacks at 6 months versus placebo, with each dosing arm compared individually.